Skip to main content
Erschienen in: Familial Cancer 2/2012

01.06.2012 | Original Article

French women’s breast self-examination practices with time after undergoing BRCA1/2 genetic testing

verfasst von: C. Maheu, T. Apostolidis, A. Petri-Cal, E. Mouret-Fourme, M. Gauthier-Villars, C. Lasset, P. Berthet, J.-P. Fricker, O. Caron, E. Luporsi, L. Gladieff, C. Noguès, C. Julian-Reynier

Erschienen in: Familial Cancer | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

To assess the impact of BRCA1/2 genetic test results on cancer-free women’s breast-self-examination (BSE) practices and to prospectively determine their influence on psychological functioning. A prospective longitudinal study on French women’s BSE practices and frequencies in BRCA1/2 carriers (N = 217) and non-carriers (N = 313) 1 and 2 years following disclosure of the test results, along with psychological factors predicting BSE practices. Before disclosure, BSE was practised by 47.2% of the women, and increased to 57.3% 1 year later. No change in the women’s practices was noted between 12 and 24 months after the test. Carriers and non-carriers practicing regularly BSE at baseline were, respectively 8 to 6 times more likely to be practising BSE regularly at 12 months after being tested. Among the carriers, having fewer depressive symptoms at baseline and believing in the ability of BSE to detect breast cancer were found to be the most decisive factors associated with BSE practices 1 year after disclosure, following adjustment for BSE baseline practices. Among the non-carriers, believing in the ability of BSE to detect breast cancer, greater post-test anxiety, and a higher perceived risk of breast cancer were found to be predictors of post-test BSE practices after adjusting for BSE baseline practices. In France, where performing BSE is neither mandatory nor recommended, an increase in BSE practices was found to occur after disclosure of women’s genetic test results, regardless of their carrier status.
Literatur
1.
Zurück zum Zitat Antoniou A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCrossRef Antoniou A et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130PubMedCrossRef
2.
Zurück zum Zitat INSERM (1996) Statistiques des causes médicales de décès 1994, in Paris: Editions INSERM 1996 INSERM (1996) Statistiques des causes médicales de décès 1994, in Paris: Editions INSERM 1996
3.
Zurück zum Zitat Publique, H.C.d.S. (1994) La santé en France, in annexes: Travaux de groupes thématiques. La Documentation Française, Paris Publique, H.C.d.S. (1994) La santé en France, in annexes: Travaux de groupes thématiques. La Documentation Française, Paris
4.
Zurück zum Zitat Eisinger F et al (1999) Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer. Lancet 353(9156):919–920PubMedCrossRef Eisinger F et al (1999) Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer. Lancet 353(9156):919–920PubMedCrossRef
5.
Zurück zum Zitat Eisinger F et al (1998) Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol 9(9):939–950PubMedCrossRef Eisinger F et al (1998) Recommendations for medical management of hereditary breast and ovarian cancer: the French National Ad Hoc Committee. Ann Oncol 9(9):939–950PubMedCrossRef
6.
Zurück zum Zitat Baxter N (2001) Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? CMAJ 164(13):1837–1846PubMed Baxter N (2001) Preventive health care, 2001 update: should women be routinely taught breast self-examination to screen for breast cancer? CMAJ 164(13):1837–1846PubMed
7.
Zurück zum Zitat Kosters JP, Gotzsche PC (2003) Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev 2:CD003373PubMed Kosters JP, Gotzsche PC (2003) Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev 2:CD003373PubMed
8.
Zurück zum Zitat Horsman D et al (2007) Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can 29(1):45–60PubMed Horsman D et al (2007) Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. J Obstet Gynaecol Can 29(1):45–60PubMed
9.
Zurück zum Zitat Kaas R et al (2008) Stage of breast cancers found during the surveillance of women with a familial or hereditary risk. Eur J Surg Oncol 34(5):501–507PubMedCrossRef Kaas R et al (2008) Stage of breast cancers found during the surveillance of women with a familial or hereditary risk. Eur J Surg Oncol 34(5):501–507PubMedCrossRef
10.
Zurück zum Zitat Kaas R, Rutgers EJ (2008) Systematic breast self-examination is not a useful screening procedure, except in hereditary or familial increased risk of breast cancer. Ned Tijdschr Geneeskd 152(43):2317–2318PubMed Kaas R, Rutgers EJ (2008) Systematic breast self-examination is not a useful screening procedure, except in hereditary or familial increased risk of breast cancer. Ned Tijdschr Geneeskd 152(43):2317–2318PubMed
11.
Zurück zum Zitat Zonderhuis BM et al (2008) Breast self-examination also valuable in women participating in a screening programme. Ned Tijdschr Geneeskd 152(43):2341–2345PubMed Zonderhuis BM et al (2008) Breast self-examination also valuable in women participating in a screening programme. Ned Tijdschr Geneeskd 152(43):2341–2345PubMed
12.
Zurück zum Zitat Hay JL, McCaul KD, Magnan RE (2006) Does worry about breast cancer predict screening behaviors? A meta-analysis of the prospective evidence. Prev Med 42(6):401–408PubMedCrossRef Hay JL, McCaul KD, Magnan RE (2006) Does worry about breast cancer predict screening behaviors? A meta-analysis of the prospective evidence. Prev Med 42(6):401–408PubMedCrossRef
13.
Zurück zum Zitat Consedine NS, Magai C, Neugut AI (2004) The contribution of emotional characteristics to breast cancer screening among women from six ethnic groups. Prev Med 38(1):64–77PubMedCrossRef Consedine NS, Magai C, Neugut AI (2004) The contribution of emotional characteristics to breast cancer screening among women from six ethnic groups. Prev Med 38(1):64–77PubMedCrossRef
14.
Zurück zum Zitat Miller SM, Shoda Y, Hurley K (1996) Applying cognitive-social theory to health-protective behavior: breast self-examination in cancer screening. Psychol Bull 119(1):70–94PubMedCrossRef Miller SM, Shoda Y, Hurley K (1996) Applying cognitive-social theory to health-protective behavior: breast self-examination in cancer screening. Psychol Bull 119(1):70–94PubMedCrossRef
15.
Zurück zum Zitat Henderson BJ et al (2008) Factors associated with breast cancer-specific distress in younger women participating in a family history mammography screening programme. Psychooncology 17(1):74–82PubMedCrossRef Henderson BJ et al (2008) Factors associated with breast cancer-specific distress in younger women participating in a family history mammography screening programme. Psychooncology 17(1):74–82PubMedCrossRef
16.
Zurück zum Zitat Parsons EP et al (2000) Reassurance through surveillance in the face of clinical uncertainty: the experience of women at risk of familial breast cancer. Health Expect 3(4):263–273PubMedCrossRef Parsons EP et al (2000) Reassurance through surveillance in the face of clinical uncertainty: the experience of women at risk of familial breast cancer. Health Expect 3(4):263–273PubMedCrossRef
17.
Zurück zum Zitat McInerney-Leo A et al (2006) BRCA1/2 testing in hereditary breast and ovarian cancer families III: risk perception and screening. Am J Med Genet A 140(20):2198–2206PubMed McInerney-Leo A et al (2006) BRCA1/2 testing in hereditary breast and ovarian cancer families III: risk perception and screening. Am J Med Genet A 140(20):2198–2206PubMed
18.
Zurück zum Zitat Claes E et al (2005) Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behav Med 31(3):93–105PubMedCrossRef Claes E et al (2005) Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behav Med 31(3):93–105PubMedCrossRef
19.
Zurück zum Zitat Bakos AD et al (2008) BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience. Health Expect 11(3):220–231PubMedCrossRef Bakos AD et al (2008) BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience. Health Expect 11(3):220–231PubMedCrossRef
20.
Zurück zum Zitat Andrieu N et al (2006) Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ Group. J Clin Oncol 24(21):3361–3366PubMedCrossRef Andrieu N et al (2006) Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators’ Group. J Clin Oncol 24(21):3361–3366PubMedCrossRef
21.
Zurück zum Zitat Horowitz M, Wilner N, Alvarez W (1979) Impact of event scale: a measure of subjective stress. Psychosom Med 41(3):209–218PubMed Horowitz M, Wilner N, Alvarez W (1979) Impact of event scale: a measure of subjective stress. Psychosom Med 41(3):209–218PubMed
22.
Zurück zum Zitat Sundin EC, Horowitz MJ (2002) Impact of event scale: psychometric properties. Br J Psychiatr 180:205–209CrossRef Sundin EC, Horowitz MJ (2002) Impact of event scale: psychometric properties. Br J Psychiatr 180:205–209CrossRef
23.
Zurück zum Zitat Thewes B, Meiser B, Hickie IB (2001) Psychometric properties of the impact of event scale amongst women at increased risk for hereditary breast cancer. Psychooncology 10(6):459–468PubMedCrossRef Thewes B, Meiser B, Hickie IB (2001) Psychometric properties of the impact of event scale amongst women at increased risk for hereditary breast cancer. Psychooncology 10(6):459–468PubMedCrossRef
24.
Zurück zum Zitat Julian-Reynier C et al (2010) Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genet Med 12(12):801–807PubMedCrossRef Julian-Reynier C et al (2010) Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genet Med 12(12):801–807PubMedCrossRef
25.
Zurück zum Zitat Fuhrer RF, Rouillon F (1989) La version française de l’échelle CES-D (Center for epidemiologic studies-depression scale). Description et traduction de l’échelle d’autoévaluation. French version of the Center for Epidemiologic Studies. Depression scale. Eur Psychiatr 4(3):163–166 Fuhrer RF, Rouillon F (1989) La version française de l’échelle CES-D (Center for epidemiologic studies-depression scale). Description et traduction de l’échelle d’autoévaluation. French version of the Center for Epidemiologic Studies. Depression scale. Eur Psychiatr 4(3):163–166
26.
Zurück zum Zitat Dorval M et al (2008) Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population. J Genet Couns 17(4):314–326PubMedCrossRef Dorval M et al (2008) Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: comparison with control population. J Genet Couns 17(4):314–326PubMedCrossRef
27.
Zurück zum Zitat Kudadjie-Gyamfi E et al (2005) Breast self-examination practices among women from six ethnic groups and the influence of cancer worry. Breast Cancer Res Treat 92(1):35–45PubMedCrossRef Kudadjie-Gyamfi E et al (2005) Breast self-examination practices among women from six ethnic groups and the influence of cancer worry. Breast Cancer Res Treat 92(1):35–45PubMedCrossRef
28.
Zurück zum Zitat Lechner L, De Nooijer J, De Vries H (2004) Breast self-examination: longitudinal predictors of intention and subsequent behaviour. Eur J Cancer Prev 13(5):369–376PubMedCrossRef Lechner L, De Nooijer J, De Vries H (2004) Breast self-examination: longitudinal predictors of intention and subsequent behaviour. Eur J Cancer Prev 13(5):369–376PubMedCrossRef
29.
Zurück zum Zitat Stefanek ME, Wilcox P (1991) First degree relatives of breast cancer patients: screening practices and provision of risk information. Cancer Detect Prev 15(5):379–384PubMed Stefanek ME, Wilcox P (1991) First degree relatives of breast cancer patients: screening practices and provision of risk information. Cancer Detect Prev 15(5):379–384PubMed
Metadaten
Titel
French women’s breast self-examination practices with time after undergoing BRCA1/2 genetic testing
verfasst von
C. Maheu
T. Apostolidis
A. Petri-Cal
E. Mouret-Fourme
M. Gauthier-Villars
C. Lasset
P. Berthet
J.-P. Fricker
O. Caron
E. Luporsi
L. Gladieff
C. Noguès
C. Julian-Reynier
Publikationsdatum
01.06.2012
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2012
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-012-9512-z

Weitere Artikel der Ausgabe 2/2012

Familial Cancer 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.